Advertisement
UK markets close in 3 hours 20 minutes
  • FTSE 100

    7,871.27
    -94.26 (-1.18%)
     
  • FTSE 250

    19,453.69
    -245.20 (-1.24%)
     
  • AIM

    741.88
    -8.40 (-1.12%)
     
  • GBP/EUR

    1.1703
    -0.0007 (-0.06%)
     
  • GBP/USD

    1.2450
    +0.0003 (+0.03%)
     
  • Bitcoin GBP

    50,513.33
    -2,620.52 (-4.93%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • DOW

    37,735.11
    -248.13 (-0.65%)
     
  • CRUDE OIL

    84.99
    -0.42 (-0.49%)
     
  • GOLD FUTURES

    2,390.20
    +7.20 (+0.30%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     
  • DAX

    17,863.10
    -163.48 (-0.91%)
     
  • CAC 40

    7,970.32
    -74.79 (-0.93%)
     

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

Could This Biosimilar Drug Candidate Be a Hit for Novartis?

On Sept. 19, Novartis (NYSE: NVS) shared positive news with investors regarding the clinical trial results for its biosimilar drug candidate to Amgen's (NASDAQ: AMGN) osteoporosis medicine Prolia. With Prolia set to lose exclusivity in the U.S. in 2025, Novartis could be close to booking some revenue from its biosimilar drug. Let's go over the outcome of the clinical trial and the U.S. osteoporosis market to figure this out.